Half-Fluence Versus Half-Dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy

Nicolò, Massimo; Eandi, Chiara M.; Alovisi, Camilla; Grignolo, Fm; Traverso, Carlo Enrico; Musetti, Donatella; Piccolino, Felice Cardillo

doi:10.1016/j.ajo.2014.01.022

Cited by 112 publications

(88 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many aspects remain to be determined, including the effects of PDT on chorioretinal atrophy, the role of PDT for patients showing no or minimal choroidal hyperpermeability, the action of PDT on the rate of recurrences and the cumulative effect of repeated treatments [52,53,54,55,56,57]. …”

Section: Treatment Optionsmentioning

confidence: 99%

Central Serous Chorioretinopathy Treatments: A Mini Review

et al. 2015

View full text Add to dashboard Cite

Central serous chorioretinopathy (CSC) is a retinal disorder that primarily affects young (20- to 50-year-old) white men, although it is seen occasionally in older patients and females. CSC is characterized by avascular focal leakage through the retinal pigment epithelium (RPE), resulting in serous detachment of the neurosensory retina. The course is usually self-limiting and in most cases resolves spontaneously within a 3-month period, with visual acuity usually recovering to 20/30 or better. However, chronic CSC may develop as a consequence of recurrences or persistent neurosensory detachment, and can result in progressive RPE atrophy and permanent visual loss. A primary involvement of the RPE and choroidal vascularization play a significant role in the pathogenesis of CSC and the current treatment options attempt to restore the functions of the RPE and the normal choroidal vasculature. The aim of the current review is to provide an overview of the current therapeutical approaches to CSC, including observation, laser treatment, photodynamic therapy with verteporfin, intravitreal anti-vascular endothelial growth factor therapy and the mineralocorticoid receptor antagonists.

show abstract

Section: Treatment Optionsmentioning

confidence: 99%

Central Serous Chorioretinopathy Treatments: A Mini Review

et al. 2015

View full text Add to dashboard Cite

show abstract

“…According to recent studies, both half-dose PDT and half-fluence PDT were as effective as standard PDT and reduced PDT-related complications [53,54]. However, whether protocol (half-dose vs. half-fluence) is superior for CSC is still controversial [55,56].…”

Section: Photodynamic Therapy (Pdt)mentioning

confidence: 99%

Review and update for central serous chorioretinopathy

Shin

2017

Hanyang Med Rev

View full text Add to dashboard Cite

“…14,15,53,54 There is limited evidence to compare these different vPDT protocols for CSC in the absence of randomised controlled trials. 44,[55][56][57][58] The current approach to management of CSC is largely empirical. There is good evidence that vPDT therapy is a useful treatment option, but published studies are limited by selection bias, lack of randomisation, small sample size, and short follow-up.…”

Section: Central Serous Chorioretinopathymentioning

confidence: 99%

Photodynamic therapy: current role in the treatment of chorioretinal conditions

Newman

2016

Eye

View full text Add to dashboard Cite

Verteporfin photodynamic therapy (vPDT) is a selective vaso-occlusive treatment that targets choroidal vascular abnormalities. It was initially developed to treat neovascular age-related macular degeneration using the 'standard' vPDT protocol (verteporfin 6 mg/ m 2 , vPDT laser fluence 50 J/cm 2 ). vPDT therapy has subsequently evolved as an important treatment modality for a range of other chorioretinal conditions including choroidal haemangioma, central serous chorioretinopathy, polypoidal choroidal vasculopathy, and peripapillary choroidal neovascularisation. Various 'safety-enhanced' vPDT protocols have been devised to optimise treatment outcomes, typically using reduced dose verteporfin (verteporfin 3 mg/m 2 ) or reduced fluence vPDT (vPDT laser fluence 25 J/cm 2 ). This paper reviews the current role of vPDT therapy in the treatment of chorioretinal conditions.

show abstract

Half-Fluence Versus Half-Dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy

Cited by 112 publications

References 19 publications

Central Serous Chorioretinopathy Treatments: A Mini Review

Central Serous Chorioretinopathy Treatments: A Mini Review

Review and update for central serous chorioretinopathy

Photodynamic therapy: current role in the treatment of chorioretinal conditions

Contact Info

Product

Resources

About